Free Access
| Issue |
Biologie Aujourd'hui
Volume 212, Number 3-4, 2018
|
|
|---|---|---|
| Page(s) | 85 - 87 | |
| DOI | https://doi.org/10.1051/jbio/2018027 | |
| Published online | 11 avril 2019 | |
- Abou-Alfa, G.K., Meyer, T., Cheng, A.L., El-Khoueiry, A.B., Rimassa, L., Ryoo, B.Y., Cicin, I., Merle, P., Chen, Y., Park, J.W., Blanc, J.F., Bolondi, L., Klümpen, H.J., Chan, S.L., Zagonel, V., Pressiani, T., Ryu, M.H., Venook, A.P., Hessel, C., Borgman-Hagey, A.E., Schwab, G., Kelley, R.K. (2018a). Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med, 379, 54-63. [CrossRef] [PubMed] [Google Scholar]
- Abou-Alfa, G.K., Chan, S.L., Furuse, J., Galle, P.R., Kelley, R.K, Qin, S., Armstrong, J., Darilay, A., Vlahovic, G., Negro, A., Sangro, B. (2018b). A randomized, multicenter phase 3 study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma: HIMALAYA study. J Clin Oncol, 36 (ASCO 2018 ; suppl ; abstr TPS4144). [Google Scholar]
- Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., Gerolami, R., Masi, G., Ross, P.J., Song, T., Bronowicki, J.P., Ollivier-Hourmand, I., Kudo, M., Cheng, A.L., Llovet, J.M., Finn, R.S., LeBerre, M.A., Baumhauer, A., Meinhardt, G., Han, G. (2017). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 389, 56-66. [Google Scholar]
- El-Khoueiry, A.B., Sangro, B., Yau, T., Crocenzi, T.H., Dastani, H.B., Melero, I. (2017). Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, 389, 2492-2502. [CrossRef] [PubMed] [Google Scholar]
- Ikeda, M., Sung M.W., Kudo, M., Kobayashi, M., Baron, A.D., Finn, R.S., Kaneko, S., Zhu, A.X., Kubota, T., Kraljevic, S., Ishikawa, K., Siegel, A.B., Kumada, H., Okusaka, T. (2018). A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol, 36, Suppl 15, 4076 [Google Scholar]
- Kudo, M., Finn, R.S., Qin, S., Han, K.H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.W., Han, G., Jassem, J., Blanc, J.F., Vogel, A., Komov, D., Evans, T.R.J., Lopez, C., Dutcus, C., Guo, M., Saito, K., Kraljevic, S., Tamai, T., Ren, M., Cheng, A.L. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet, 391, 1163-1173. [CrossRef] [PubMed] [Google Scholar]
- Pishvaian, M.J., Lee, M.S., Ryoo, B.Y., Stein, S., Lee, K.H., Verret, W., Spahn, J., Shao, H., Liu, B., Iizuka, K., Hsu, C.H. (2018). Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Ann Oncol, 29, Suppl 8, LBA 26. [Google Scholar]
- Qin, S.K., Ren, Z.G., Meng, Z.Q., Chen, Z.D., Chai, X.L., Xiong, J.P., Bai, Y.X., Yang, L., Zhu, H., Fang, W.J., Lin, X.Y., Chen, X.M., Li, E.X., Xia, Y., Zou, J.J. (2018). A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma who failed or intolerable to prior systemic treatment. Ann Oncol, 29, Suppl 8, LBA 27. [Google Scholar]
- Zhu, A.X., Park, J.O., Ryoo, B.Y., Yen, C.J., Poon, R., Pastorelli, D., Blanc, J.F., Chung, H.C., Baron, A.D., Pfiffer, T.E., Okusaka, T., Kubackova, K., Trojan, J., Sastre, J., Chau I., Chang, S.C., Abada, P.B., Yang, L., Schwartz, J.D., Kudo, M. (2015). Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol, 16, 859-870. [CrossRef] [PubMed] [Google Scholar]
- Zhu, A.X., Baron, A.D., Malfertheiner, P., Kudo, M., Kawazoe, S., Pezet, D., Weissinger, F., Brandi, G., Barone, C.A., Okusaka, T., Wada, Y., Park, J.O., Ryoo, B.Y., Cho, J.Y., Chung, H.C., Li, C.P., Yen, C.J., Lee, K.D., Chang, S.C., Yang, L., Abada, P.B., Chau, I. (2017). Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Analysis of REACH trial results by Child-Pugh Score. JAMA Oncol, 3, 235-243. [Google Scholar]
- Zhu, A.X., Finn, R.S., Galle, P.R., Llovet, J.M., Blanc, J.F., Okusaka, T., Chau, I., Cella, D., Girvan, A., Gable, J., Bowman, L., Hsu, P., Abada, B., Kudo M. (2018a). Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH). Ann Oncol, 29(8). [Google Scholar]
- Zhu, A.X., Finn, R.S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., Sarker, D., Verset, G., Chan, S.L., Knox, J., Daniele, B., Webber, A.L., Ebbinghaus, S.W., Ma, J., Siegel, A.B., Cheng, A.L., Kudo, M. (2018b). Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol, 19, 940-952. [CrossRef] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.